Arterial pulmonary hypertension (PAH) is a rare complication in patients with metabolic syndrome. A good glycemic control is related to a better prognosis in diabetic patients with PAH. The presence of GLP-1 receptors in the lungs and the fact that this incretin promotes vasorelaxation in the pulmonary artery, place the incretin-based therapy as a possible treatment in patients with PAH. This case report will show the effect of vildagliptin -a DPP4 inhibitor -on the improvement of pulmonary symptoms and hemodynamic patterns in a patient with type 2 diabetes mellitus and PAH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.